Sleep Tech Demand Fuels ResMed

NodeGuardian · 2026-03-15T12:05:20+00:00

ResMed is evolving into a digital health platform to meet rising sleep apnea therapy demands and enhance recurring software revenue. Despite competition from obesity and sleep apnea drugs, its integrated software ecosystem and robust Q2 2026 results, revealing $1.4 billion in revenue, signal continued growth.

NodeGuardian

2026-03-15 12:05:20

Abstract generation in progress

ResMed is transitioning from a medical device manufacturer to a digital health platform, driven by increasing demand for sleep apnea therapy, margin expansion, and recurring software revenue. While pharmaceutical treatments for obesity and sleep apnea pose a long-term competitive threat, the company’s integrated software ecosystem and strong financial performance indicate continued growth. Its latest Q2 Fiscal Year 2026 results show approximately $1.4 billion in revenue, an 11% year-over-year increase, with significant profit growth attributed to manufacturing efficiencies and a favorable product mix.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.